FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/XiikNr3hWO https://t.co/Xd66zgvoDv

Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/c4mYjdLKW7 https://t.co/lXh5klx0cq

SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo). https://t.co/k5SAshxdsg https://t.co/tMtRHn2C6j

Registration is now open! Early bird pricing is available until 11/30/23. See you there! https://t.co/zjXyldwlyl https://t.co/CpQ00745c1

#PMR: Is There Hidden GCA? Dr. Anisha Dua, asks the question: in PMR should you worry about occult GCA? https://t.co/Cd6u2GwJuo @anisha_dua https://t.co/dWUH4zudPc

UK researchers develop a human vascularised synovium-on-a-chip: mechanically stimulated, 3D, microfluidic device w/ synovial cells and blood vessel cells to investigate syn inflammation & monocyte recruitment, mimics the forces applied w/ joint movement https://t.co/qlRHSE3o2b https://t.co/dsKvcsyysa

Turkish study 1,134 PsA pts found mean Dx delay=35 mos (median: 12). 39% Dx w/in 3 mos, & 67% w/in 24 mos. Dx delay decr. over time: 60 to 24 mos (<2010 to 2015–2019). Dx delay factors: less education (OR 2.6), arthritis>PSO (1.7), LBP 1st (1.6)https://t.co/q6aqtcaTxS https://t.co/uZSgoYuxJT

#PMR with Cancer Dr. Sebastian Sattui (Pittsburgh, PA) Can PMR be a paraneoplastic presentation? QD Clinics are video vignettes with lessons from the clinic. https://t.co/YhTkKpmzIl @sattuiSEMD https://t.co/FTsz3QA5Cn

IL-6 Inhibitors in #PMR: Give early or late? https://t.co/tMdriuFPYB https://t.co/WMhuogIMJC

Draw Your Arthralgias Featuring Dr. David Liew (Melbourne, Australia) 54 yr old with polyarthralgias, & slightly abnormal labs; could this be #PMR? https://t.co/siP6Kv1Z1X https://t.co/cMy5ZTybUn

FDA Approves IV Secukinumab On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) https://t.co/yt2GtawuDp https://t.co/FUMFnIXFkk

Surprising Link Between Weight Gain and RA Activity In patients with RA treated with infliximab (Remicade), increases in body mass index (BMI) scores over time were not associated with increased disease activity or faster radiographic progression. https://t.co/hXuJbwiY7B https://t.co/G88CTkSlB5